SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Supriya Lifescience - Quaterly Results

28 Oct 2024 Evaluate
A fair growth of 18.56% in the revenue at Rs. 1661.02 millions was reported in the September 2024 quarter as compared to Rs. 1400.95 millions during year-ago period.Handsome Net Profit growth of 93.22% reported above the corresponding previous quarter figure of Rs. 461.49 millions to Rs. 238.84 millions.Operating Profit saw a handsome growth to 672.35 millions from 342.19 millions in the quarter ended September 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202409 202309 % Var 202409 202309 % Var 202403 202303 % Var
Sales 1661.02 1400.95 18.56 3267.28 2721.16 20.07 5703.70 4609.38 23.74
Other Income 25.18 24.67 2.07 47.42 53.85 -11.94 106.35 94.89 12.08
PBIDT 672.35 342.19 96.48 1320.01 816.28 61.71 1836.11 1383.87 32.68
Interest 4.27 4.60 -7.17 7.62 12.76 -40.28 21.10 30.84 -31.58
PBDT 668.08 337.59 97.90 1312.39 803.52 63.33 1815.01 1353.03 34.14
Depreciation 47.44 39.81 19.17 94.00 79.36 18.45 158.11 118.15 33.82
PBT 620.64 297.78 108.42 1218.39 724.16 68.25 1656.90 1234.88 34.17
TAX 159.15 58.94 170.02 310.46 200.20 55.07 465.76 336.30 38.50
Deferred Tax 4.69 -26.44 -117.74 9.33 15.19 -38.58 94.76 29.49 221.33
PAT 461.49 238.84 93.22 907.93 523.96 73.28 1191.14 898.58 32.56
Equity 160.97 160.97 0.00 160.97 160.97 0.00 160.97 160.97 0.00
PBIDTM(%) 40.48 24.43 65.72 40.40 30.00 34.68 32.19 30.02 7.22

Supriya Lifescience Share Price

636.90 -1.05 (-0.16%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×